



**CURRICULUM VITAE**

**Stuart Fischer, MD, FACC, FACP, FSCAI, CCDS**  
**Co-Founder of Los Alamitos Cardiovascular, 1985**

5300 Katella Avenue, Los Alamitos, CA 90720

p: (562) 430-7533 | f: (562) 430-8055 | website: [www.losalcardio.com](http://www.losalcardio.com)

<b>Specialties:</b>	<b>Cardiovascular Diseases, Interventional Cardiology, Endovascular Diseases</b>
<b>Board Certifications:</b>	<ul style="list-style-type: none"> <li>• <b>Certified in Internal Medicine, Cardiovascular Disease and Interventional Cardiology</b> National Board of Physicians and Surgeons 2015-2017</li> <li>• <b>Certified in Interventional Cardiology</b> American Board of Internal Medicine 1999 (Recertification 2011 – 2021)</li> <li>• <b>Certified Cardiac Device Specialist (CCDS)</b> International Board of Heart Rhythm Examiners (IBHRE) Certification Examination for Competency in Cardiac Rhythm Device Therapy for the Physician 1988</li> <li>• <b>Certified in Cardiovascular Disease</b> American Board of Internal Medicine 1985</li> <li>• <b>Certified in Internal Medicine</b> American Board of Internal Medicine 1982</li> </ul>
<b>Research Experience:</b>	<ul style="list-style-type: none"> <li>• <b>AEGIS:</b> A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects with Acute Coronary Syndrome. Principal Investigator   2019 Sponsor: CSL Behring LLC NCT03473223: <a href="https://clinicaltrials.gov/ct2/show/NCT03473223">https://clinicaltrials.gov/ct2/show/NCT03473223</a></li> </ul>

- **COVET** : Comparison of Oral anticoagulants for extended Venous Thromboembolism (COVET). It is a randomized, open label, active comparator to determine whether the direct oral anticoagulant apixaban and rivaroxaban are safer than warfarin (fewer bleeding complications) and still as effective as warfarin (no increase in recurrent blood clots).  
Sub-Investigator | 2018 – Present  
Sponsor : Patient-Centered Outcomes Research Institute (PCORI)  
NCT03196349: <https://clinicaltrials.gov/ct2/show/NCT03196349>
- **NODE 301**: Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Efficacy, and Safety Study of Etripamil Nasal Spray for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia.  
Sub-Investigator | 2019  
Sponsor: Milestone Pharmaceuticals Inc.  
NCT03464019: <https://clinicaltrials.gov/ct2/show/NCT03464019>
- **NODE 302**: Multi-Centre, Open-Label, Safety Study of Etripamil Nasal Spray in Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia (Extension of NODE-301).  
Sub-Investigator | 2019  
Sponsor: Milestone Pharmaceuticals Inc.  
NCT03635996: <https://clinicaltrials.gov/ct2/show/NCT03635996>
- **PARADISE MI**: A multi-center, randomized, double-blind, active-controlled, parallel-group Phase 3 study to evaluate the efficacy and safety of LCZ696 compared to ramipril on morbidity and mortality in high risk patients following an acute myocardial infarction.  
Principal Investigator | 2018 – Present  
Sponsor: Novartis  
NCT02924727: <https://clinicaltrials.gov/ct2/show/NCT02924727>
- **PEA-VALVE**: Phono- and Electrocardiogram Assisted Detection of Valvular Disease. This is data collection of recorded heart sounds + ECGs using Eko Duo and Eko Core devices to further refine and validate algorithms using de-identified diagnosis confirmed by gold-standard echocardiograms.  
Sub-Investigator | 2018 – Present  
Sponsor: Eko Devices
- **GALACTIC-HF**: Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction.  
Sub-Investigator | 2017 – Present  
Sponsor: Amgen  
NCT02929329: <https://clinicaltrials.gov/ct2/show/NCT02929329>

- **PROVE-HF:** A 52 Week, Open Label Evaluation of the Effects of Sacubitril/Valsartan (LCZ696) Therapy on Biomarkers, Myocardial Remodeling and Patient-reported Outcomes in Heart Failure With Reduced Left Ventricular Ejection Fraction.  
 Primary Investigator | 2017 – 2019  
 Sponsor: Novartis  
 NCT02887183: <https://clinicaltrials.gov/ct2/show/NCT02887183>
- **Barostim Therapy for Heart Failure (BeAT-HF):** The Barostim Neo - Baroreflex Activation Therapy for Heart Failure is a prospective, randomized trial in subjects with reduced ejection fraction heart failure.  
 Sub-Investigator | 2016 – Present  
 Sponsor: CVRx, Inc.  
 NCT02627196: <https://clinicaltrials.gov/show/NCT02627196>
- **MLHFQ Study:** Evaluate and establish content validity of the Minnesota Living with Heart Failure Questionnaire (MLHFQ) in patients with Symptomatic Hypertrophic Cardiomyopathy.  
 Sub-Investigator | 2016 – 2017  
 Sponsor: Gilead/ICON
- **THEMIS- A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus (THEMIS):** A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Ticagrelor Twice Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients With Type 2 Diabetes Mellitus (THEMIS - Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study).  
 Primary Investigator | 2015 – Present  
 Sponsor: AstraZeneca  
 NCT01991795: <https://clinicaltrials.gov/show/NCT01991795>
- Retrospective Medical Records Review of Participants Interviewed for Study M-12347 (Concept Elicitation Focus Groups and Cognitive Interviews to Develop a New Patient Reported Outcome Instrument in Chronic Heart Failure).  
 Primary Investigator | 2015 – 2016  
 Sponsor: Amgen, Evidera
- **DECLARE-TIMI 58 Dapagliflozin Effect on CardiovascuLAR Events:** A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes.  
 Sub-Investigator | 2013 – 2018  
 Sponsor: AstraZeneca  
 NCT01730534 | <http://clinicaltrials.gov/ct2/show/NCT01730534>

- **ODYSSEY EFC11570:** A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome  
Principal Investigator | 2013 – 2017  
Sponsor: Sanofi  
NCT01663402 | <http://clinicaltrials.gov/ct2/show/NCT01663402>
- **SILVER-AMI Risk Stratification in Older Persons with Acute Myocardial Infarction.**  
Principal Investigator | 2013 – 2017  
Sponsor: Yale University School of Medicine/NIH  
NCT01755052 | <http://clinicaltrials.gov/ct2/show/NCT01755052>
- **RivaroxAFL3003:** An Open Label Study Exploring two treatment strategies in patients with Atrial Fibrillation who undergo Percutaneous Coronary Intervention.  
Sub-Investigator | 2013 – 2014  
Sponsor: Janssen Scientific Affairs/Johnson & Johnson
- **Phase III Trial to confirm the Anti-Anginal effect of T-89 in patients with Stable Angina.**  
Sub-Investigator | 2013  
Sponsor: Tasly Pharmaceuticals  
NCT0169580 | <http://clinicaltrials.gov/ct2/show/NCT0169580>
- **Cardiovascular Inflammation Reduction Trial (CIRT):** Cardiovascular Inflammation Reduction Trial (CIRT): Event Driven Trial of weekly Low-Dose Methotrexate in prevention of recurrent cardiovascular events among stable post myocardial infarction patients with Type II Diabetes or Metabolic Syndrome.  
Sub-Investigator | 2013 – 2018  
Sponsor: Center for Cardiovascular Disease Prevention Brigham and Women's Hospital/ National Heart Lung and Blood Institute  
NCT01594333 | <http://clinicaltrials.gov/ct2/show/NCT01594333>
- **User Comprehension Evaluation of a New Cleaning and Disinfection Procedure for the INRatio® 2 PT/INR Monitoring System (ADAPT) BSTE-0159.**  
Sub-Investigator | 2012  
Sponsor: Alere San Diego

- **Mission® PT Coagulation Monitoring System Clinical Study.**  
Sub-Investigator | 2012  
Sponsor: ACON Laboratories, INC.
- **The “BRIDGE” Trial (1U01HL08675501A1):** Bridging Anticoagulation in Patients Who Require Temporary Interruption of Warfarin Therapy for an Elective Invasive Procedure or Surgery.  
Sub-Investigator | 2012 – 2015  
Sponsor: National Institutes of Health (NIH)-National Heart, Lung and Blood Institute (NHLBI)  
NCT00786474 | <http://clinicaltrials.gov/ct2/show/NCT00786474>
- **GLORIA-AF 1160.129:** Global Registry on Long-Term Oral Anti-thrombotic Treatment in Patients with Atrial Fibrillation Phase II-III.  
Sub-Investigator | 2012 – Present  
Sponsor: Boehringer Ingelheim  
NCT01468701 | <http://clinicaltrials.gov/ct2/show/NCT01468701>
- **BRADY-CARE:** Advanced Bradycardia Device Feature Utilization and Clinical Outcomes.  
Sub-Investigator | 2010 – 2012  
Sponsor: St. Jude Medical Center  
NCT01062126 | <http://clinicaltrials.gov/ct2/show/NCT01062126>
- **The PROMISE Trial:** PROspective Multicenter Imaging Study for Evaluation of Chest Pain.  
Sub-Investigator | 2010 – 2014  
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)  
NCT01174550 | <http://clinicaltrials.gov/ct2/show/record/NCT01174550>
- **ORBIT-AF I and II:** Outcomes Registry for Better Informed Treatment of Atrial Fibrillation.  
Sub-Investigator | 2010 – 2017  
Sponsor: Janssen Scientific Affairs, LLC  
Collaborator: Duke Clinical Research  
NCT01165710 | <http://clinicaltrials.gov/ct2/show/NCT01165710>  
NCT01701817 | <http://clinicaltrials.gov/ct2/show/NCT01701817>
- **RATE:** Registry of Atrial Tachyarrhythmia/Atrial Fibrillation (AT/AF) Episodes in the Cardiac Rhythm Management (CRM) Device Population.  
Sub-Investigator | 2008 – 2010  
Sponsor: St. Jude Medical Center  
NCT00837798 | <http://clinicaltrials.gov/ct2/show/NCT00837798>

	<ul style="list-style-type: none"> <li>• <b>FREEDOM:</b> A Frequent Optimization Study the Quick Opt™ Method. Sub-Investigator   2008 – 2010 Sponsor: St. Jude Medical Center NCT00418314   <a href="http://clinicaltrials.gov/ct2/show/NCT00418314">http://clinicaltrials.gov/ct2/show/NCT00418314</a></li>   <li>• <b>ENGAGE:</b> Phase III, randomized, double-blind, double-dummy, parallel group, multi-center, multi-national study for evaluation of efficacy and safety of DU-176b versus Warfarin in subjects with Atrial Fibrillation - Effective Anticoagulation with Xa next Generation in Atrial Fibrillation (ENGAGE - AF TIMI - 48). Sub-Investigator   2009 – 2015 Sponsor: Daiichi Sankyo Pharma Development NCT00781391   <a href="http://clinicaltrials.gov/ct2/show/record/NCT00781391">http://clinicaltrials.gov/ct2/show/record/NCT00781391</a></li>   <li>• Phase III, double-blind, randomized, placebo-controlled, multi-center study evaluating the efficacy and safety of Dalcetrapib on lipids, lipoproteins, apolipoproteins and markers of CV Risk in patients hospitalized for an acute coronary syndrome (ACS) when treatment is initiated within 1 week after an ACS (Dal-ACUTE). Sub-Investigator   2008 – 2012 Sponsor: F. Hoffmann-La Roche Ltd., Hoffmann-La Roche, Inc. , Roche Global Development. NCT01323153   <a href="http://clinicaltrials.gov/ct2/show/NCT01323153">http://clinicaltrials.gov/ct2/show/NCT01323153</a></li>   <li>• Multi-center, randomized, controlled study to investigate the safety and tolerability of Intravenous Ferric Carboxymaltose (FCM) vs. Iron Dextran in treating iron deficiency anemia in subjects who are not dialysis dependent. Sub-Investigator   2007 – 2009 Sponsor: Luitpold Pharmaceuticals, Inc. NCT00704028   <a href="http://clinicaltrials.gov/ct2/show/NCT00704028">http://clinicaltrials.gov/ct2/show/NCT00704028</a></li>   <li>• Echocardiographic Assessment of Mitral Stenosis, Two-Dimensional Echocardiography versus Doppler Pressure Half Time Exercise Echocardiography in Coronary Artery Disease Doppler Mitral Flow in Various Pathologic States Thin-Line Bi-Polar Pacemaker Leads. Department of Physiology, Albany Medical College Sponsor: Intermedics</li> </ul>
<b>Current Hospital Appointments:</b>	<ul style="list-style-type: none"> <li>• <b>Los Alamitos Medical Center</b> <b>Active staff since April 1985</b></li> </ul>

	<p>3751 Katella Avenue Los Alamitos, California 90720</p> <ul style="list-style-type: none"> <li>• <b>MemorialCare Health System Long Beach Memorial Medical Center Active staff since December 1985</b> 2801 Atlantic Avenue Long Beach, California 90801</li> </ul>
<b>Other Hospital Affiliations:</b>	<ul style="list-style-type: none"> <li>• <b>Memorial Heart Institute Founding Fellow, January 1987</b></li> <li>• <b>University of California, Irvine Courtesy Staff since April 1986</b></li> </ul>
<b>Committees:</b>	<p><i>Los Alamitos Medical Center</i></p> <ul style="list-style-type: none"> <li>• <b>Chairman, Credentials Committee, 1996 – Present</b></li> <li>• <b>Member, Governing Board: 1994 – 2001, 2004 – Present</b></li> <li>• <b>Chief of Staff, 1994 – 1995</b></li> <li>• <b>Vice Chief of Staff, 1993</b></li> <li>• <b>Chairman, Quality Assurance Committee, 1993</b></li> <li>• <b>Chairman, Critical Care Committee, 1989</b></li> <li>• <b>Chairman, Department of Medicine, 1990 – 1992</b></li> <li>• <b>Member, Executive Committee, 1989 – Present</b></li> <li>• <b>Director Cardiac Catheterization Lab, 1989 – 2013</b></li> <li>• <b>Director, Pacemaker Clinic, 1985-2007</b></li> <li>• <b>Director, Echocardiography Lab, 1985 – 1997</b></li> <li>• <b>Secretary-Treasurer Medical Staff, 1992</b></li> </ul> <p><i>Long Beach Memorial Medical Center</i></p> <ul style="list-style-type: none"> <li>• <b>Member Interventional Cardiology Sub-Committee , 1997 – Present</b></li> <li>• <b>Member Cardiology Credentials and QA Committee, 1996 – Present</b></li> </ul> <p><i>Lakewood Regional Medical Center</i></p> <ul style="list-style-type: none"> <li>• <b>Member, Executive Committee: 2000 – 2001, 2004 – 2007</b></li> <li>• <b>Director, Cardiac Catheterization Lab, 2002 – 2005</b></li> </ul>
<b>Professional Societies:</b>	<ul style="list-style-type: none"> <li>• <b>American College of Cardiology (FACC) Fellow</b></li> <li>• <b>American College of Physicians (FACP) Fellow</b></li> <li>• <b>The Society for Cardiac Angiography and Interventions (FSCAI) Fellow</b></li> </ul>

	<ul style="list-style-type: none"> <li>• <b>Heart Rhythm Society-IBHRE CCDS</b> Member</li> <li>• <b>The Society of Geriatric Cardiology (FSGC)</b> Fellow</li> </ul>
<b>Academic Appointments:</b>	<ul style="list-style-type: none"> <li>• <b>Co-Director Interventional Fellowship Program</b> University of California, Irvine/Long Beach Memorial Hospital July 2000 – Present</li> <li>• <b>Assistant Clinical Professor of Medicine</b> University of California, Irvine July 1989 – Present</li> </ul>
<b>Work History:</b>	<ul style="list-style-type: none"> <li>• <b>Los Alamitos Cardiovascular/Los Alamitos Internal Group, Inc.</b> Cardiologist Los Alamitos, California 1985 – Present</li> <li>• <b>Fischer Mangold Group</b> Emergency Medicine St. Francis - St. George Hospital Cincinnati, Ohio 1982 – 1983</li> <li>• <b>Medical Health Service</b> Staffing Three Cincinnati ER's (Part Time) Cincinnati, Ohio 1980 – 1983</li> <li>• <b>Bethesda Hospital</b> Critical Care Physician (Part Time) Cincinnati, Ohio 1981 – 1983</li> </ul>
<b>Professional Recognition:</b>	<ul style="list-style-type: none"> <li>• <b>American Medical Association Physician's Recognition Award in Continuing Medical Education</b> January 2008 – January 2011</li> <li>• <b>Sarah Lipson Seigal Memorial Award for Research</b> 1973</li> </ul>
<b>Publications:</b>	<ul style="list-style-type: none"> <li>• Kumar P, Agarwal P, VanNatta B, Shandling A, <b>Fischer S</b>, McAtee P, Messenger J. "Clinical evaluation of ThinLine II (models 430-25 and 438-25 Intermedics) bipolar pacing leads." <i>PACE</i>. 1999; 22 Part II 869.</li> </ul>



	<ul style="list-style-type: none"> <li>• Dabestani A, Takenaka K, Allen B, Gardin J, <b>Fischer S</b>, Russell D, Henry W. "Effects of Spontaneous Respiration on Diastolic Left Ventricular Filling Assessed by Pulsed Doppler Echocardiography." <i>Am J Cardiol</i> . 1988; 61:1356-1358.</li> </ul>
<b>Education:</b>	<ul style="list-style-type: none"> <li>• <b>Cardiovascular Diseases Fellowship</b> <b>University of California, Irvine</b> Division of Cardiology Orange, California Walter L. Henry, MD, Chief 1983 – 1985</li> <li>• <b>Internal Medicine Residency</b> <b>University of Cincinnati Medical Center</b> Department of Internal Medicine Cincinnati, Ohio Martin Goldberg, MD, Chair 1980 – 1982</li> <li>• <b>Straight Medical Internship</b> <b>University of Cincinnati Medical Center</b> Department of Internal Medicine Cincinnati, Ohio Martin Goldberg, MD, Chair 1979 – 1980</li> <li>• <b>Medical Education</b> <b>Cornell University Medical College</b> New York, New York 1977 – 1979</li> <li>• <b>Medical Education</b> Universita di Sassari Faculta di Medicinav Sassari, Italy 1973 – 1977</li> <li>• <b>Undergraduate Education</b> <b>Brooklyn College</b> Brooklyn, New York BS, Biology, 1969 – 1973</li> </ul>
<b>Clinical Expertise:</b>	<b>Non-Invasive Cardiology:</b>

	<p>Echocardiography – TEE, Dobutamine and Stress Echo</p> <p><b>Invasive-Interventional Cardiovascular and Endovascular Diseases:</b>  Catheterization, PTCA, Atherectomy, Stents, Laser Atherectomy, VBT, Pacing,  Peripheral Vascular Disease, Peripheral Interventions, and Current Level II  certification for performing and interpreting MDCTA</p>
<p><b>Medical Licenses:</b></p>	<p><b>California , New York, Ohio</b></p>
<p><b>Local Organizations:</b></p>	<p><b>Rotary 1986 – 1989</b></p>